ArTS Archivio della ricerca di Trieste

ROCCA, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.023
NA - Nord America 897
EU - Europa 729
SA - Sud America 85
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.751
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 885
SG - Singapore 469
HK - Hong Kong 325
IT - Italia 263
CN - Cina 140
BR - Brasile 76
NL - Olanda 76
SE - Svezia 70
CH - Svizzera 62
RU - Federazione Russa 62
DE - Germania 61
IN - India 32
FR - Francia 31
IE - Irlanda 24
FI - Finlandia 19
AT - Austria 15
KR - Corea 15
GB - Regno Unito 10
AE - Emirati Arabi Uniti 8
BE - Belgio 6
SN - Senegal 6
CA - Canada 5
JP - Giappone 5
MX - Messico 5
TR - Turchia 5
UA - Ucraina 5
BG - Bulgaria 4
CZ - Repubblica Ceca 4
MA - Marocco 4
RO - Romania 4
AR - Argentina 3
BD - Bangladesh 3
EC - Ecuador 3
PL - Polonia 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
CL - Cile 2
GR - Grecia 2
ID - Indonesia 2
IR - Iran 2
JO - Giordania 2
PH - Filippine 2
SI - Slovenia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
CI - Costa d'Avorio 1
ES - Italia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
NO - Norvegia 1
PA - Panama 1
PK - Pakistan 1
TH - Thailandia 1
TN - Tunisia 1
Totale 2.751
Salva come PNG Salva come JPEG
Città #
Hong Kong 324
Singapore 270
Boardman 156
Santa Clara 69
Trieste 68
Bern 59
Beijing 52
Columbus 48
Ashburn 39
Princeton 32
Moscow 29
Dublin 24
North Bergen 22
Pune 19
Seattle 18
São Paulo 18
Milan 17
Düsseldorf 15
Fairfield 15
Seoul 15
Boydton 14
Los Angeles 14
Rome 14
Helsinki 13
Nuremberg 13
Frankfurt am Main 12
Houston 12
Tappahannock 11
Chandler 10
Treviso 10
Shanghai 9
Wilmington 9
The Dalles 8
Vienna 8
Woodbridge 8
Lauterbourg 7
London 7
Brasília 6
Brussels 6
Dakar 6
Duino-Aurisina 6
San Donà di Piave 6
Torviscosa 6
Ann Arbor 5
Dallas 5
L’Aquila 5
Amsterdam 4
Ankara 4
Annecy 4
Cambridge 4
Dongguan 4
Hangzhou 4
Iesi 4
Jacksonville 4
Lappeenranta 4
Novara 4
Phoenix 4
Santos 4
Schaumburg 4
Sofia 4
Springfield 4
West Jordan 4
Azzano Decimo 3
Bologna 3
Chieti 3
Coyoacán 3
Dubai 3
Fort Worth 3
Guangzhou 3
Mirano 3
New York 3
Newark 3
Nilópolis 3
Philadelphia 3
Prineville 3
Pristina 3
Raleigh 3
Taichung 3
Tangier 3
Tokyo 3
Udine 3
Venice 3
Washington 3
Amman 2
Athens 2
Bengaluru 2
Benito Juarez 2
Bibione 2
Bolzano 2
Brno 2
Calenzano 2
Castelfranco Emilia 2
Castelli Calepio 2
Cesano Maderno 2
Chalon-sur-Saône 2
Changsha 2
Cividale del Friuli 2
Deiva Marina 2
Dhaka 2
Dresden 2
Totale 1.700
Salva come PNG Salva come JPEG
Nome #
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer 119
Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT 106
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial 100
A tailored machine learning approach for mortality prediction in severe COVID-19 treated with glucocorticoids 85
Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 82
Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report 69
179 C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma 64
The Predictive and Prognostic Role of RAS-RAF-MEK-ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets 60
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 54
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 47
Can Systems Biology Advance Clinical Precision Oncology? 46
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer 43
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 43
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 42
Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial 41
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy? 41
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer 40
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study 39
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 39
A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer 39
Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression 39
Ribociclib and Endocrine Therapy in Breast Cancer 38
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemo-immunotherapy in patients with advanced melanoma 38
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels 38
Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter 37
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ 37
Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy 36
WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis 36
Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas 36
Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? 36
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study 36
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 36
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer 35
Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype 35
A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer 33
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 33
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 32
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 31
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer 31
Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience 30
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 30
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 30
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy 30
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer 29
Androgen receptor signaling pathways as a target for breast cancer treatment 28
The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings 28
Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer 28
A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer 27
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer 27
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 27
Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study 26
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer 26
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer 25
Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population? 24
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer. A case report 24
Precision medicine: PI3K targeting in advanced breast cancer 24
Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer 24
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 23
Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial 22
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy 20
[Prophylaxis of toxic effects on the peripheral venous system associated with intravenous administration of vinorelbine] 20
Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence 19
Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer 16
Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients 16
Association between hepatitis C virus and non-Hodgkin's lymphoma, and effects of viral infection on histologic subtype and clinical course 16
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer 15
CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience 15
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel 15
Radiotherapy, morphine, and bone pain: a difficult relationship? 15
Circulating tumor cells in early breast cancer: A connection with vascular invasion 15
Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer 14
Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients 13
Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy 13
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 12
Diagnosis and management of neck metastases from an unknown primary 12
CTCs in early breast cancer: A path worth taking 11
Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study 11
Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer 11
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer 11
Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy 10
Breast cancer vaccines: a clinical reality or fairy tale? 10
Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy 10
Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience 10
Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients 10
Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review 10
Cell-free DNA detected by "liquid biopsy" as a potential prognostic biomarker in early breast cancer 9
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer? 8
Update: current management issues in malignant melanoma 8
Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer 8
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors 8
Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer 8
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer 8
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy 8
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy 8
Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase 7
Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors 7
Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (Ann Oncol 2004; 15: 1543-1550): ... and in humans? 7
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects 7
Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents 7
Progress with palbociclib in breast cancer: latest evidence and clinical considerations 7
Totale 2.869
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.292
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.292
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203 0 0 0 0 0 0 0 0 0 0 2 1
2020/202125 4 13 0 1 2 0 1 1 1 0 1 1
2021/202251 1 0 0 0 0 1 0 2 1 14 3 29
2022/2023470 16 2 9 19 32 65 2 100 101 8 95 21
2023/2024701 89 43 32 63 63 54 92 112 20 35 65 33
2024/20251.658 19 167 308 104 157 114 226 88 265 172 38 0
Totale 2.958